Xeomin

Clinical safety rating: caution

Comprehensive clinical and safety monograph for Xeomin (Xeomin).

How it works

IncobotulinumtoxinA inhibits acetylcholine release at the neuromuscular junction by cleaving SNAP-25, a presynaptic protein, thereby blocking neurotransmission and causing muscle paralysis.

What the body does with it

Metabolism	Presumed to undergo proteolytic degradation via general protein catabolism; no specific metabolic pathways or enzymes identified.
Excretion	Renal (minimal, intact toxin degraded); biliary/fecal (primary, via hepatic metabolism and biliary excretion of inactive fragments).
Half-life	Terminal elimination half-life: approximately 10 days (range 6–16 days) for the neurotoxin complex in serum; clinical duration of effect is longer due to prolonged intraneuronal activity.
Protein binding	Approximately 85–95% bound to serum proteins, primarily albumin and alpha-2-macroglobulin.
Volume of Distribution	Approximately 0.5–1.0 L/kg, indicating distribution primarily into extracellular fluid and muscle tissue.
Bioavailability	Intramuscular: 100% (direct injection into muscle); oral: negligible (not clinically used); intravenous: not applicable.
Onset of Action	Intramuscular: 1–3 days (initial effect), maximal effect at 2–4 weeks.
Duration of Action	Intramuscular: 3–6 months, depending on dose, muscle mass, and individual response; repeated injections may lead to shorter duration due to antibody formation.

Classification & Brands

Dosing & administration

Injected intramuscularly; for cervical dystonia: 120-240 Units divided among affected muscles every 12-16 weeks; for blepharospasm: 15-35 Units per eye every 12-16 weeks; for glabellar lines: 20 Units divided into 5 injection sites every 3-4 months.

Dosage form	INJECTABLE
Renal impairment	No dose adjustment required for any degree of renal impairment.
Liver impairment	No dose adjustment required for any degree of hepatic impairment.
Pediatric use	Safety and efficacy not established in patients <18 years; no approved pediatric dosing.
Geriatric use	No specific dose adjustment recommended, but consider increased sensitivity and comorbidities; use lowest effective dose and monitor for adverse effects.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for Xeomin (Xeomin).

Breastfeeding	No studies in breastfeeding women; excretion into human milk is unlikely due to high molecular weight (>150 kDa). M/P ratio not determined. Use with caution only if clearly indicated.
Teratogenic Risk	Insufficient human data; animal studies not indicative of increased fetal risk at doses up to 4 U/kg. Given high molecular weight (>150 kDa), systemic absorption is negligible, minimizing fetal exposure. No known teratogenic effects across trimesters.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

WARNING: DISTANT SPREAD OF TOXIN EFFECT - The effects of botulinum toxin may spread from the area of injection to other areas of the body, causing symptoms similar to those of botulism. These symptoms have been reported hours to weeks after injection, and in some cases have been life-threatening. Risk is greatest in children treated for spasticity, but symptoms also occurred in adults. Seek medical attention immediately if swallowing or breathing difficulties occur.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to any botulinum toxin preparation or any component of the formulation","Intended use for intramuscular injection at the suggested administration sites","Presence of infection at the proposed injection site(s)"]

Clinical Precautions

Precautions

["Distant spread of toxin effect (black box warning)","Dysphagia and breathing difficulties","Pre-existing neuromuscular disorders may exacerbate weakness","Risk of aspiration in patients with pre-existing swallowing disorders","Injection site reactions","Antibody formation with repeated use","Use with caution in patients with compromised respiratory status","Concomitant use with aminoglycosides or other agents interfering with neuromuscular transmission may potentiate effects"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

Xeomin

Clinical safety rating: caution

Comprehensive clinical and safety monograph for Xeomin (Xeomin).

How it works

IncobotulinumtoxinA inhibits acetylcholine release at the neuromuscular junction by cleaving SNAP-25, a presynaptic protein, thereby blocking neurotransmission and causing muscle paralysis.

What the body does with it

Metabolism	Presumed to undergo proteolytic degradation via general protein catabolism; no specific metabolic pathways or enzymes identified.
Excretion	Renal (minimal, intact toxin degraded); biliary/fecal (primary, via hepatic metabolism and biliary excretion of inactive fragments).
Half-life	Terminal elimination half-life: approximately 10 days (range 6–16 days) for the neurotoxin complex in serum; clinical duration of effect is longer due to prolonged intraneuronal activity.
Protein binding	Approximately 85–95% bound to serum proteins, primarily albumin and alpha-2-macroglobulin.
Volume of Distribution	Approximately 0.5–1.0 L/kg, indicating distribution primarily into extracellular fluid and muscle tissue.
Bioavailability	Intramuscular: 100% (direct injection into muscle); oral: negligible (not clinically used); intravenous: not applicable.
Onset of Action	Intramuscular: 1–3 days (initial effect), maximal effect at 2–4 weeks.
Duration of Action	Intramuscular: 3–6 months, depending on dose, muscle mass, and individual response; repeated injections may lead to shorter duration due to antibody formation.

Classification & Brands

Dosing & administration

Dosage form	INJECTABLE
Renal impairment	No dose adjustment required for any degree of renal impairment.
Liver impairment	No dose adjustment required for any degree of hepatic impairment.
Pediatric use	Safety and efficacy not established in patients <18 years; no approved pediatric dosing.
Geriatric use	No specific dose adjustment recommended, but consider increased sensitivity and comorbidities; use lowest effective dose and monitor for adverse effects.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for Xeomin (Xeomin).

Breastfeeding	No studies in breastfeeding women; excretion into human milk is unlikely due to high molecular weight (>150 kDa). M/P ratio not determined. Use with caution only if clearly indicated.
Teratogenic Risk	Insufficient human data; animal studies not indicative of increased fetal risk at doses up to 4 U/kg. Given high molecular weight (>150 kDa), systemic absorption is negligible, minimizing fetal exposure. No known teratogenic effects across trimesters.
Fetal Monitoring